Abarceo Pharma AB
Adam Bruce is an experienced executive with a significant background in the pharmaceutical and biotechnology sectors. Since March 2002, Adam has served as the Chief Executive Officer, Founder, and Board Member of TikoMed AB, where leadership spans across various roles, including Working Chairman. Since July 2020, Adam has been the Chairman of Abarceo Pharma, where efforts are directed towards innovative solutions for Type 2 Diabetes. Adam also owns WaveSeven AB, active since 2014. Educational credentials include a degree from Lund University (1993-1999), completion of Styrelse Akademin (2010), and participation in the Executive Foundation program at the Lund School of Economics and Management (2007-2008).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Abarceo Pharma AB
Abarceo Pharma is a spin out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD and Associate Prof. Albert Salehi are world-class experts in beta cell biology. Abarceo Pharma is a Lund University Holding company and was founded in December 2017. The company is dedicated to developingnovel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.